Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

T 3011

Next Previous
Drug Profile

T 3011

Alternative Names: B-015; MVR-T3011; MVR-T3011 IT; T-3 - ImmVira Pharma; T-3011

Latest Information Update: 16 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immvira Pharma
  • Developer Immvira Pharma; Shanghai Pharmaceuticals Holding
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cell death stimulants; Immunologic cytotoxicity; Interleukin-12 expression stimulants; Programmed cell death 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer; Breast cancer; Head and neck cancer; Malignant melanoma; Sarcoma
  • Phase I/II Non-small cell lung cancer; Solid tumours
  • Phase I Ascites; Colorectal cancer
  • No development reported Skin cancer

Most Recent Events

  • 30 May 2025 Phase-II clinical trials in Bladder cancer (Second-line therapy or greater) in China (Intravesicular)
  • 14 May 2025 Phase-II clinical trials in Bladder cancer (Second-line therapy or greater) in USA (Intravesicular) (NCT06971614)
  • 16 Sep 2024 Adverse events and efficacy data from a phase I trial in Bladder cancer released by ImmVira

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top